个人中心 - 老虎社区

Y2301156

IP属地：广东

帖子 · 157帖子 · 157
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Y2301156Y2301156
  ·04-17
  $衢州发展(600208)$ 今天涨得也还行
  162 评论
  1
  分享
  举报
- Y2301156Y2301156
  ·04-17
  $宝济药业-B(02659)$ 公司公告其自主研发的注射用人玻璃酸酶已于3月31日获得国家药监局批准上市，用于辅助皮下输液。这是公司继SJ02后第二款获批上市的核心产品
  296 评论
  1
  分享
  举报
- Y2301156Y2301156
  ·04-17
  $黑芝麻智能(02533)$ 跨场景的技术复用与生态协同，驱动公司内在价值进入加速裂变的新阶段，打开了未来的成长空间
  439 评论
  1
  分享
  举报
- Y2301156Y2301156
  ·04-15
  $派格生物医药-B(02565)$ 2025年公司研发开支为5038.7万元，并已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵，体现了其持续的创新投入
  99 评论
  1
  分享
  举报
- Y2301156Y2301156
  ·04-13
  $中国建材(03323)$ 利空出尽是利好
  317 评论
  1
  分享
  举报
- Y2301156Y2301156
  ·04-13
  $智谱(02513)$ 数据显示，智谱MaaS开放平台/API业务的年度经常性收入（ARR）已达约17亿元，过去一年增长60倍；2026年一季度API调用定价较去年底提升83%，但调用量仍同比增长400%，成为国内付费Token消耗量最高的厂商之一
  749 评论
  1
  分享
  举报
- Y2301156Y2301156
  ·04-09
  $晶泰控股(02228)$ 市场给予其较高估值倍数的核心逻辑在于其平台属性、管线期权价值以及技术跨行业复制的潜力，而非简单的短期盈利
  351 评论
  1
  分享
  举报
- Y2301156Y2301156
  ·04-02
  $宝地矿业(601121)$ 表现得波澜不惊
  252 评论
  点赞
  分享
  举报
- Y2301156Y2301156
  ·04-02
  $晶泰控股(02228)$ 公司第一大外部股东为腾讯，持股11.96%；其他重要股东包括红杉中国（持股7.79%）和中国人寿（持股6.90%）,都是顶级产业与财务资本
  721 评论
  点赞
  分享
  举报
- Y2301156Y2301156
  ·03-31
  $津药药业(600488)$ 药业终于可以发威了
  500 评论
  点赞
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4203909980173582","uuid":"4203909980173582","gmtCreate":1740806802561,"gmtModify":1740837164671,"name":"Y2301156","pinyin":"y2301156","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":6,"tweetSize":157,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":554443228966968,"gmtCreate":1776396779031,"gmtModify":1776396781205,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/600208\">$衢州发展(600208)$ </a> 今天涨得也还行","listText":"<a href=\"https://laohu8.com/S/600208\">$衢州发展(600208)$ </a> 今天涨得也还行","text":"$衢州发展(600208)$ 今天涨得也还行","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/554443228966968","isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":554443497809040,"gmtCreate":1776396752670,"gmtModify":1776396754844,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02659\">$宝济药业-B(02659)$ </a> 公司公告其自主研发的注射用人玻璃酸酶已于3月31日获得国家药监局批准上市，用于辅助皮下输液。这是公司继SJ02后第二款获批上市的核心产品","listText":"<a href=\"https://laohu8.com/S/02659\">$宝济药业-B(02659)$ </a> 公司公告其自主研发的注射用人玻璃酸酶已于3月31日获得国家药监局批准上市，用于辅助皮下输液。这是公司继SJ02后第二款获批上市的核心产品","text":"$宝济药业-B(02659)$ 公司公告其自主研发的注射用人玻璃酸酶已于3月31日获得国家药监局批准上市，用于辅助皮下输液。这是公司继SJ02后第二款获批上市的核心产品","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/554443497809040","isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":554442997442344,"gmtCreate":1776396697469,"gmtModify":1776396699864,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02533\">$黑芝麻智能(02533)$&nbsp;</a> 跨场景的技术复用与生态协同，驱动公司内在价值进入加速裂变的新阶段，打开了未来的成长空间","listText":"<a href=\"https://laohu8.com/S/02533\">$黑芝麻智能(02533)$&nbsp;</a> 跨场景的技术复用与生态协同，驱动公司内在价值进入加速裂变的新阶段，打开了未来的成长空间","text":"$黑芝麻智能(02533)$ 跨场景的技术复用与生态协同，驱动公司内在价值进入加速裂变的新阶段，打开了未来的成长空间","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/554442997442344","isVote":1,"tweetType":1,"viewCount":439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":553827218170200,"gmtCreate":1776246288478,"gmtModify":1776246290438,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 2025年公司研发开支为5038.7万元，并已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵，体现了其持续的创新投入","listText":"<a href=\"https://laohu8.com/S/02565\">$派格生物医药-B(02565)$ </a> 2025年公司研发开支为5038.7万元，并已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵，体现了其持续的创新投入","text":"$派格生物医药-B(02565)$ 2025年公司研发开支为5038.7万元，并已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵，体现了其持续的创新投入","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/553827218170200","isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":553122414187152,"gmtCreate":1776074219035,"gmtModify":1776074221145,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/03323\">$中国建材(03323)$ </a> 利空出尽是利好","listText":"<a href=\"https://laohu8.com/S/03323\">$中国建材(03323)$ </a> 利空出尽是利好","text":"$中国建材(03323)$ 利空出尽是利好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/553122414187152","isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":553122315284792,"gmtCreate":1776074192817,"gmtModify":1776074194990,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02513\">$智谱(02513)$ </a> 数据显示，智谱MaaS开放平台/API业务的年度经常性收入（ARR）已达约17亿元，过去一年增长60倍；2026年一季度API调用定价较去年底提升83%，但调用量仍同比增长400%，成为国内付费Token消耗量最高的厂商之一","listText":"<a href=\"https://laohu8.com/S/02513\">$智谱(02513)$ </a> 数据显示，智谱MaaS开放平台/API业务的年度经常性收入（ARR）已达约17亿元，过去一年增长60倍；2026年一季度API调用定价较去年底提升83%，但调用量仍同比增长400%，成为国内付费Token消耗量最高的厂商之一","text":"$智谱(02513)$ 数据显示，智谱MaaS开放平台/API业务的年度经常性收入（ARR）已达约17亿元，过去一年增长60倍；2026年一季度API调用定价较去年底提升83%，但调用量仍同比增长400%，成为国内付费Token消耗量最高的厂商之一","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/553122315284792","isVote":1,"tweetType":1,"viewCount":749,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":551767332099752,"gmtCreate":1775730685553,"gmtModify":1775730687921,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02228\">$晶泰控股(02228)$ </a> 市场给予其较高估值倍数的核心逻辑在于其平台属性、管线期权价值以及技术跨行业复制的潜力，而非简单的短期盈利","listText":"<a href=\"https://laohu8.com/S/02228\">$晶泰控股(02228)$ </a> 市场给予其较高估值倍数的核心逻辑在于其平台属性、管线期权价值以及技术跨行业复制的潜力，而非简单的短期盈利","text":"$晶泰控股(02228)$ 市场给予其较高估值倍数的核心逻辑在于其平台属性、管线期权价值以及技术跨行业复制的潜力，而非简单的短期盈利","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/551767332099752","isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":549165525148656,"gmtCreate":1775095450752,"gmtModify":1775095452741,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/601121\">$宝地矿业(601121)$ </a> 表现得波澜不惊","listText":"<a href=\"https://laohu8.com/S/601121\">$宝地矿业(601121)$ </a> 表现得波澜不惊","text":"$宝地矿业(601121)$ 表现得波澜不惊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/549165525148656","isVote":1,"tweetType":1,"viewCount":252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":549165481255272,"gmtCreate":1775095420571,"gmtModify":1775095422705,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02228\">$晶泰控股(02228)$ </a> 公司第一大外部股东为腾讯，持股11.96%；其他重要股东包括红杉中国（持股7.79%）和中国人寿（持股6.90%）,都是顶级产业与财务资本","listText":"<a href=\"https://laohu8.com/S/02228\">$晶泰控股(02228)$ </a> 公司第一大外部股东为腾讯，持股11.96%；其他重要股东包括红杉中国（持股7.79%）和中国人寿（持股6.90%）,都是顶级产业与财务资本","text":"$晶泰控股(02228)$ 公司第一大外部股东为腾讯，持股11.96%；其他重要股东包括红杉中国（持股7.79%）和中国人寿（持股6.90%）,都是顶级产业与财务资本","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/549165481255272","isVote":1,"tweetType":1,"viewCount":721,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":548557070321464,"gmtCreate":1774948619886,"gmtModify":1774948622462,"author":{"id":"4203909980173582","authorId":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4203909980173582","authorIdStr":"4203909980173582"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/600488\">$津药药业(600488)$ </a> 药业终于可以发威了","listText":"<a href=\"https://laohu8.com/S/600488\">$津药药业(600488)$ </a> 药业终于可以发威了","text":"$津药药业(600488)$ 药业终于可以发威了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/548557070321464","isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}